원격 케어 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 지역별, 부문 예측(2025-2030년)

Telecare Market Growth & Trends:

The global telecare market size is estimated to reach USD 6.34 billion by 2030, registering a CAGR of 4.79% from 2025 to 2030, according to a new report by Grand View Research, Inc. Telecare provides services mainly to vulnerable and elderly individuals for immediate contact with someone for help in case of any emergency. In addition, the increasing development of new technology, from telephones to online virtual visits, has shaped the face of modern healthcare services. Thus, technological advancements have played a crucial role in driving the market growth. Innovations, such as wearable devices, remote monitoring systems, and telemedicine platforms, have revolutionized healthcare delivery by enabling real-time health monitoring, virtual consultations, and remote patient management. For instance, in June 2023, Telecare introduced RxPad, Australia's standalone platform for electronic prescriptions.

Designed by clinicians for clinicians, this innovative solution aims to replace traditional paper prescriptions. RxPad is poised to revolutionize healthcare delivery, improving patient experiences and empowering doctors, making consultations more efficient and enjoyable for everyone involved. This innovative device offers the most advanced features in the market. Moreover, the growing aging population is a significant factor propelling market expansion. With the growing aging population, the demand for healthcare services increases, particularly for chronic disease management and elderly care. Telecare offers a viable solution to meet these demands by providing continuous monitoring and support for older adults. It enables elderly patients to live independently while ensuring they receive timely medical attention.

This demographic shift is creating a substantial market for telecare solutions that cater to the specific needs of older individuals, promoting safety, health, and well-being in an aging society. Furthermore, the increasing prevalence of chronic diseases and rising demand for personalized healthcare solutions have propelled the adoption of telecare technologies. Chronic conditions, such as diabetes, hypertension, and heart disease, require continuous monitoring and management, which can be effectively facilitated through remote monitoring solutions. Telecare enables proactive disease management, early detection of complications, and timely interventions, leading to improved patient outcomes and reduced healthcare costs in the long run. The market is poised for continued growth as healthcare stakeholders recognize the transformative potential of remote monitoring and care management solutions in delivering accessible, cost-effective, and patient-centered healthcare services.

Telecare Market Report Highlights:

• The remote medication management segment led the market with the largest revenue share of 50.97% in 2024, attributed to several factors, including the aging population, increased prevalence of chronic diseases, development of elderly telecare apps and technological advancements.
• The activity monitoring segment is anticipated to grow at the significant CAGR over the forecast period, owing to technological advancements and the increasing demand for improved healthcare access and outcomes.
• North America dominated the telecare market with the largest revenue share of 49.13% in 2024, attributed to several factors such as the high penetration of smartphones and the internet, growing awareness among individuals to maintain physical health and the use of remote healthcare services.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Telecare Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Aging population and elderly care needs for telecare
    • 3.2.1.2. Technological improvements in AI and ML
    • 3.2.1.3. Advances in wearable health technology
    • 3.2.1.4. Growing shift to home healthcare services
    • 3.2.1.5. Increased focus on chronic disease management
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Privacy and security concerns over patient data
    • 3.2.2.2. Complexity of regulatory compliance
    • 3.2.2.3. Lack of standardization across platforms
    • 3.2.2.4. Limited insurance reimbursement for telecare services
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Leveraging ai, big data, and predictive analytics
    • 3.2.3.2. Collaborations with healthcare providers and insurers
    • 3.2.3.3. Increased focus on mental health and remote counseling
  • 3.2.4. Market challenges analysis
    • 3.2.4.1. Connectivity and infrastructure gaps in rural areas
    • 3.2.4.2. Resistance from healthcare providers and traditional systems
• 3.3. Telecare: Market Analysis Tools
  • 3.3.1. Industry analysis - Porter's
  • 3.3.2. PESTLE analysis
• 3.4. Telecare Market: Accomplishments and Opportunities Across the Health System Sectors
• 3.5. Analysis on Start-ups and Established Companies in Telecare Market
• 3.6. Regulatory Landscape, By Country
  • 3.6.1. Regulatory overview
  • 3.6.2. Health data privacy and security laws
  • 3.6.3. Telemedicine licensing and reimbursement policies
  • 3.6.4. Government initiatives and support
  • 3.6.5. Emerging trends in regulatory compliance
• 3.7. Value Chain Analysis
  • 3.7.1. Telecare value chain overview
  • 3.7.2. Key stakeholders and their roles
  • 3.7.3. Technology providers and platforms
  • 3.7.4. Service delivery and interoperability
  • 3.7.5. Distribution and supply chain management
  • 3.7.6. Revenue streams and business models
  • 3.7.7. Challenges in the value chain
• 3.8. Technology Landscape
  • 3.8.1. Technological advancements driving telecare
  • 3.8.2. Telecare software and applications
  • 3.8.3. Data analytics and artificial intelligence
  • 3.8.4. Wearable devices and IoT integration
  • 3.8.5. Telecommunication infrastructure
• 3.9. Case Study Analysis
• 3.10. Funding/Investment Trends Scenario
  • 3.10.1. Venture capital (VC) deal activity
  • 3.10.2. Top 10 digital health VC deals in 2024
  • 3.10.3. Annual equity funding & deals
  • 3.10.4. Quarterly equity funding & deals
  • 3.10.5. Quarter funding & deals by global region
  • 3.10.6. Percent of quarterly deals by global region
  • 3.10.7. Percent of quarterly deals by investor group
  • 3.10.8. Annual average & median deal size
  • 3.10.9. Annual median deal size by global region
  • 3.10.10. Annual median deal size by investor group
  • 3.10.11. Annual mega-round funding & deals
  • 3.10.12. Quarterly funding & deals from mega-rounds (deals worth usd 100 million+)
  • 3.10.13. Quarter mega-round funding & deals by global region
  • 3.10.14. Quarterly mega-round deals by global region
  • 3.10.15. Quarterly mega-rounds as percentage of funding
  • 3.10.16. Quarter top equity deals
  • 3.10.17. Annual percentage of deals by deal stage
  • 3.10.18. Quarter regional deal shares by deal stage
  • 3.10.19. Annual median funding by deal stage
  • 3.10.20. Quarter top seed/angel deals
  • 3.10.21. Quarter top series A deals
  • 3.10.22. Quarter top series B deals
  • 3.10.23. Quarter top series C deals
  • 3.10.24. Quarter top series D deals
  • 3.10.25. Quarter top series E+ deals
• 3.11. Unicorn Funding Trends in Digital Health
  • 3.11.1. Quarterly new & total unicorns (private companies valued at USD 1 billion+)
  • 3.11.2. Quarter new & total unicorns by global region
  • 3.11.3. Quarterly new unicorns by global region
  • 3.11.4. Quarter top unicorns by valuation
• 3.12. Exit Trends in Digital Health Market
  • 3.12.1. Annual exits
  • 3.12.2. Quarterly exits
  • 3.12.3. Percent of quarterly exits by global region
  • 3.12.4. Quarter top M&A exits
  • 3.12.5. Quarter top IPOs
• 3.13. Key Investors Analysis in the Digital Health Landscape
  • 3.13.1. Quarter top investors by company count
  • 3.13.2. Quarter top VCs by company count
  • 3.13.3. Quarter top corporate VCs (CVCs) by company count
• 3.14. Key Investment Geographic Trends in Digital Health Market
  • 3.14.1. U.S. Trends
    • 3.14.1.1. Annual funding & deals
    • 3.14.1.2. Quarterly funding & deals
    • 3.14.1.3. Annual percentage of deals by deal stage
    • 3.14.1.4. Quarter top equity deals
    • 3.14.1.5. Annual exits
    • 3.14.1.6. Quarterly exists
    • 3.14.1.7. Quarter top investors by company count
  • 3.14.2. Asia Trends
    • 3.14.2.1. Annual funding & deals
    • 3.14.2.2. Quarterly funding & deals
    • 3.14.2.3. Annual percentage of deals by deal stage
    • 3.14.2.4. Quarter top equity deals
    • 3.14.2.5. Annual exits
    • 3.14.2.6. Quarterly exists
    • 3.14.2.7. Quarter top investors by company count
  • 3.14.3. China
  • 3.14.4. Japan
  • 3.14.5. Europe Trends
    • 3.14.5.1. Annual funding & deals
    • 3.14.5.2. Quarterly funding & deals
    • 3.14.5.3. Annual percentage of deals by deal stage
    • 3.14.5.4. Quarter top equity deals
    • 3.14.5.5. Annual exits
    • 3.14.5.6. Quarterly exists
    • 3.14.5.7. Quarter top investors by company count
  • 3.14.6. UK

Chapter 4. Telecare Market Segment Analysis, By Type, 2018-2030 (USD Million)

• 4.1. Definition and Scope
• 4.2. Type Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Telecare Market, by Type, 2018 to 2030
• 4.5. Activity Monitoring
  • 4.5.1. Activity Monitoring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Remote Medication Management
  • 4.6.1. Remote Medication Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Telecare Market Segment Analysis, By Region, 2018- 2030 (USD Million)

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Regional Market Snapshot
• 5.4. Telecare Market Share by Region, 2024 & 2030:
• 5.5. North America
  • 5.5.1. North America telecare market, 2018 - 2030 (USD Million)
  • 5.5.2. U.S.
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Scenario
    • 5.5.2.3. Competitive Scenario
    • 5.5.2.4. U.S. telecare market, 2018 - 2030 (USD Million)
  • 5.5.3. Canada
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Scenario
    • 5.5.3.3. Competitive Scenario
    • 5.5.3.4. Canada telecare market, 2018 - 2030 (USD Million)
  • 5.5.4. Mexico
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Scenario
    • 5.5.4.3. Competitive Scenario
    • 5.5.4.4. Mexico telecare market, 2018 - 2030 (USD Million)
• 5.6. Europe
  • 5.6.1. Europe telecare market, 2018 - 2030 (USD Million)
  • 5.6.2. UK
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Scenario
    • 5.6.2.3. Competitive Scenario
    • 5.6.2.4. UK telecare market, 2018 - 2030 (USD Million)
  • 5.6.3. Germany
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Scenario
    • 5.6.3.3. Competitive Scenario
    • 5.6.3.4. Germany telecare market, 2018 - 2030 (USD Million)
  • 5.6.4. France
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Scenario
    • 5.6.4.3. Competitive Scenario
    • 5.6.4.4. France telecare market, 2018 - 2030 (USD Million)
  • 5.6.5. Italy
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Scenario
    • 5.6.5.3. Competitive Scenario
    • 5.6.5.4. Italy telecare market, 2018 - 2030 (USD Million)
  • 5.6.6. Spain
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Scenario
    • 5.6.6.3. Competitive Scenario
    • 5.6.6.4. Spain telecare market, 2018 - 2030 (USD Million)
  • 5.6.7. Norway
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Regulatory Scenario
    • 5.6.7.3. Competitive Scenario
    • 5.6.7.4. Norway telecare market, 2018 - 2030 (USD Million)
  • 5.6.8. Sweden
    • 5.6.8.1. Key Country Dynamics
    • 5.6.8.2. Regulatory Scenario
    • 5.6.8.3. Competitive Scenario
    • 5.6.8.4. Sweden telecare market, 2018 - 2030 (USD Million)
  • 5.6.9. Denmark
    • 5.6.9.1. Key Country Dynamics
    • 5.6.9.2. Regulatory Scenario
    • 5.6.9.3. Competitive Scenario
    • 5.6.9.4. Denmark telecare market, 2018 - 2030 (USD Million)
• 5.7. Asia Pacific
  • 5.7.1. Asia Pacific telecare market, 2018 - 2030 (USD Million)
  • 5.7.2. Japan
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Scenario
    • 5.7.2.3. Competitive Scenario
    • 5.7.2.4. Japan telecare market, 2018 - 2030 (USD Million)
  • 5.7.3. China
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Scenario
    • 5.7.3.3. Competitive Scenario
    • 5.7.3.4. China telecare market, 2018 - 2030 (USD Million)
  • 5.7.4. India
    • 5.7.4.1. Key Country Dynamics
    • 5.7.4.2. Regulatory Scenario
    • 5.7.4.3. Competitive Scenario
    • 5.7.4.4. India telecare market, 2018 - 2030 (USD Million)
  • 5.7.5. Australia
    • 5.7.5.1. Key Country Dynamics
    • 5.7.5.2. Regulatory Scenario
    • 5.7.5.3. Competitive Scenario
    • 5.7.5.4. Australia telecare market, 2018 - 2030 (USD Million)
  • 5.7.6. South Korea
    • 5.7.6.1. Key Country Dynamics
    • 5.7.6.2. Regulatory Scenario
    • 5.7.6.3. Competitive Scenario
    • 5.7.6.4. South Korea telecare market, 2018 - 2030 (USD Million)
  • 5.7.7. Thailand
    • 5.7.7.1. Key Country Dynamics
    • 5.7.7.2. Regulatory Scenario
    • 5.7.7.3. Competitive Scenario
    • 5.7.7.4. Thailand telecare market, 2018 - 2030 (USD Million)
• 5.8. Latin America
  • 5.8.1. Latin America telecare market, 2018 - 2030 (USD Million)
  • 5.8.2. Brazil
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Scenario
    • 5.8.2.3. Competitive Scenario
    • 5.8.2.4. Brazil telecare market, 2018 - 2030 (USD Million)
  • 5.8.3. Argentina
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Scenario
    • 5.8.3.3. Competitive Scenario
    • 5.8.3.4. Argentina telecare market, 2018 - 2030 (USD Million)
• 5.9. MEA
  • 5.9.1. MEA telecare market, 2018 - 2030 (USD Million)
  • 5.9.2. South Africa
    • 5.9.2.1. Key Country Dynamics
    • 5.9.2.2. Regulatory Scenario
    • 5.9.2.3. Competitive Scenario
    • 5.9.2.4. South Africa telecare market, 2018 - 2030 (USD Million)
  • 5.9.3. Saudi Arabia
    • 5.9.3.1. Key Country Dynamics
    • 5.9.3.2. Regulatory Scenario
    • 5.9.3.3. Competitive Scenario
    • 5.9.3.4. Saudi Arabia telecare market, 2018 - 2030 (USD Million)
  • 5.9.4. UAE
    • 5.9.4.1. Key Country Dynamics
    • 5.9.4.2. Regulatory Scenario
    • 5.9.4.3. Competitive Scenario
    • 5.9.4.4. UAE telecare market, 2018 - 2030 (USD Million)
  • 5.9.5. Kuwait
    • 5.9.5.1. Key Country Dynamics
    • 5.9.5.2. Regulatory Scenario
    • 5.9.5.3. Competitive Scenario
    • 5.9.5.4. Kuwait telecare market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company Categorization
• 6.3. Company Position Analysis
• 6.4. Company Evaluation Metrix
• 6.5. Company Profiles
  • 6.5.1. Teladoc Health, Inc.
    • 6.5.1.1. Company overview
    • 6.5.1.2. Financial performance
    • 6.5.1.3. Product benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Abbott Laboratories
    • 6.5.2.1. Company overview
    • 6.5.2.2. Financial performance
    • 6.5.2.3. Product benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Johnson and Johnson
    • 6.5.3.1. Company overview
    • 6.5.3.2. Financial performance
    • 6.5.3.3. Product benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. AstraZeneca PLC
    • 6.5.4.1. Company overview
    • 6.5.4.2. Financial performance
    • 6.5.4.3. Product benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. F. Hoffmann-La Roche Ltd.
    • 6.5.5.1. Company overview
    • 6.5.5.2. Financial performance
    • 6.5.5.3. Product benchmarking
    • 6.5.5.4. Strategic initiatives
  • 6.5.6. Novartis AG
    • 6.5.6.1. Company overview
    • 6.5.6.2. Financial performance
    • 6.5.6.3. Product benchmarking
    • 6.5.6.4. Strategic initiatives
  • 6.5.7. NeoRehab
    • 6.5.7.1. Company overview
    • 6.5.7.2. Financial performance
    • 6.5.7.3. Product benchmarking
    • 6.5.7.4. Strategic initiatives
  • 6.5.8. Bristol-Myers Squibb Company
    • 6.5.8.1. Company overview
    • 6.5.8.2. Financial performance
    • 6.5.8.3. Product benchmarking
    • 6.5.8.4. Strategic initiatives
  • 6.5.9. GlaxoSmithKline plc
    • 6.5.9.1. Company overview
    • 6.5.9.2. Financial performance
    • 6.5.9.3. Product benchmarking
    • 6.5.9.4. Strategic initiatives
  • 6.5.10. Merck and Co., Inc.
    • 6.5.10.1. Company overview
    • 6.5.10.2. Financial performance
    • 6.5.10.3. Product benchmarking
    • 6.5.10.4. Strategic initiatives
  • 6.5.11. Pfizer, Inc.
    • 6.5.11.1. Company overview
    • 6.5.11.2. Financial performance
    • 6.5.11.3. Product benchmarking
    • 6.5.11.4. Strategic initiatives
  • 6.5.12. Sanofi
    • 6.5.12.1. Company overview
    • 6.5.12.2. Financial performance
    • 6.5.12.3. Product benchmarking
    • 6.5.12.4. Strategic initiatives
  • 6.5.13. Samsung Electronics Co. Ltd
    • 6.5.13.1. Company overview
    • 6.5.13.2. Financial performance
    • 6.5.13.3. Product benchmarking
    • 6.5.13.4. Strategic initiatives
  • 6.5.14. Qualcomm Technologies, Inc.
    • 6.5.14.1. Company overview
    • 6.5.14.2. Financial performance
    • 6.5.14.3. Product benchmarking
    • 6.5.14.4. Strategic initiatives
  • 6.5.15. Orange
    • 6.5.15.1. Company overview
    • 6.5.15.2. Financial performance
    • 6.5.15.3. Product benchmarking
    • 6.5.15.4. Strategic initiatives
  • 6.5.16. Google (Alphabet), Inc
    • 6.5.16.1. Company overview
    • 6.5.16.2. Financial performance
    • 6.5.16.3. Product benchmarking
    • 6.5.16.4. Strategic initiatives
  • 6.5.17. Allscripts
    • 6.5.17.1. Company overview
    • 6.5.17.2. Financial performance
    • 6.5.17.3. Product benchmarking
    • 6.5.17.4. Strategic initiatives
  • 6.5.18. Apple, Inc.
    • 6.5.18.1. Company overview
    • 6.5.18.2. Financial performance
    • 6.5.18.3. Product benchmarking
    • 6.5.18.4. Strategic initiatives
  • 6.5.19. AT&T
    • 6.5.19.1. Company overview
    • 6.5.19.2. Financial performance
    • 6.5.19.3. Product benchmarking
    • 6.5.19.4. Strategic initiatives
  • 6.5.20. Airstrip Technologies, Inc
    • 6.5.20.1. Company overview
    • 6.5.20.2. Financial performance
    • 6.5.20.3. Product benchmarking
    • 6.5.20.4. Strategic initiatives